Daniel L. Menezes

2.2k total citations
38 papers, 592 citations indexed

About

Daniel L. Menezes is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Daniel L. Menezes has authored 38 papers receiving a total of 592 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hematology, 17 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in Daniel L. Menezes's work include Acute Myeloid Leukemia Research (24 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers) and Histone Deacetylase Inhibitors Research (6 papers). Daniel L. Menezes is often cited by papers focused on Acute Myeloid Leukemia Research (24 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers) and Histone Deacetylase Inhibitors Research (6 papers). Daniel L. Menezes collaborates with scholars based in United States, Germany and Canada. Daniel L. Menezes's co-authors include Carla Heise, Helen Ye, Arnold B. Gelb, Sharon L. Aukerman, Emil Samara, Sang Hoon Lee, Evelyn N. Garrett, Lawrence D. Mayer, Alex L. Harris and Jayesh Vora and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Daniel L. Menezes

36 papers receiving 585 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel L. Menezes United States 12 403 189 141 78 76 38 592
Koshi Akahane Japan 14 301 0.7× 217 1.1× 181 1.3× 44 0.6× 94 1.2× 63 658
Sharon Friedlander United States 10 437 1.1× 333 1.8× 146 1.0× 124 1.6× 76 1.0× 35 748
Nguyen Tan United States 4 343 0.9× 179 0.9× 131 0.9× 34 0.4× 67 0.9× 7 460
Dina Ali Sweden 4 298 0.7× 264 1.4× 103 0.7× 67 0.9× 53 0.7× 5 460
Paul A. Algate United States 7 269 0.7× 146 0.8× 68 0.5× 112 1.4× 58 0.8× 12 528
Davide Torti Italy 12 418 1.0× 304 1.6× 63 0.4× 116 1.5× 60 0.8× 17 677
S. Pezzulli United States 10 403 1.0× 352 1.9× 142 1.0× 94 1.2× 38 0.5× 19 704
X. Zhang United States 10 336 0.8× 170 0.9× 226 1.6× 183 2.3× 65 0.9× 35 709
Dan Lu China 9 458 1.1× 203 1.1× 52 0.4× 85 1.1× 35 0.5× 16 694
Glenn Michelson United States 14 340 0.8× 282 1.5× 146 1.0× 72 0.9× 83 1.1× 51 668

Countries citing papers authored by Daniel L. Menezes

Since Specialization
Citations

This map shows the geographic impact of Daniel L. Menezes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel L. Menezes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel L. Menezes more than expected).

Fields of papers citing papers by Daniel L. Menezes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel L. Menezes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel L. Menezes. The network helps show where Daniel L. Menezes may publish in the future.

Co-authorship network of co-authors of Daniel L. Menezes

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel L. Menezes. A scholar is included among the top collaborators of Daniel L. Menezes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel L. Menezes. Daniel L. Menezes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bewersdorf, Jan Philipp, Rory M. Shallis, Ethan Thompson, et al.. (2025). Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. Therapeutic Advances in Hematology. 16. 1584265104–1584265104.
2.
Zeidan, Amer M., Jan Philipp Bewersdorf, Rory M. Shallis, et al.. (2024). Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine. Therapeutic Advances in Hematology. 15. 1574175664–1574175664. 8 indexed citations
3.
Voso, Maria Teresa, Stéphane de Botton, Michael Pfeilstöcker, et al.. (2024). A post-hoc analysis of outcomes of patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) who received oral azacitidine (Oral-AZA) maintenance therapy in the QUAZAR AML-001 study.. Journal of Clinical Oncology. 42(16_suppl). 6522–6522. 1 indexed citations
4.
Garcia‐Manero, Guillermo, Karen Yee, Francisca Hernández, et al.. (2024). Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial.. Journal of Clinical Oncology. 42(16_suppl). 6509–6509. 1 indexed citations
5.
Ravandi, Farhad, Hartmut Döhner, Andrew H. Wei, et al.. (2023). Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML‐001. British Journal of Haematology. 204(3). 877–886. 2 indexed citations
6.
Menezes, Daniel L., Andrew H. Wei, Hartmut Döhner, et al.. (2023). P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML-001 TRIAL. HemaSphere. 7(S3). e930876b–e930876b. 1 indexed citations
7.
8.
Menezes, Daniel L., Wendy L. See, Alberto Risueño, et al.. (2023). Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML‐001 trial. British Journal of Haematology. 201(6). 1129–1143. 3 indexed citations
9.
Zeidan, Amer M., Jan Philipp Bewersdorf, Rory M. Shallis, et al.. (2022). Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy. Leukemia. 37(1). 240–243. 10 indexed citations
10.
Roboz, Gail J., Farhad Ravandi, Andrew H. Wei, et al.. (2022). Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. Blood. 139(14). 2145–2155. 37 indexed citations
11.
Jeyaraju, Danny V., Sheida Hayati, Ann Polonskaia, et al.. (2022). Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial. Blood. 140(Supplement 1). 3865–3867. 1 indexed citations
12.
13.
Wang, Xiaomin, et al.. (2021). Quantification of azacitidine incorporation into human DNA/RNA by accelerator mass spectrometry as direct measure of target engagement. Journal of Pharmaceutical and Biomedical Analysis. 202. 114152–114152. 1 indexed citations
14.
Levy, Benjamin, Giuseppe Giaccone, Benjamin Besse, et al.. (2019). Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. European Journal of Cancer. 108. 120–128. 48 indexed citations
15.
Ponath, Paul, Daniel L. Menezes, Chin Pan, et al.. (2018). A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer. Clinical Cancer Research. 24(20). 5178–5189. 39 indexed citations
16.
Han, Wooseok, Daniel L. Menezes, Yongjin Xu, et al.. (2016). Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model. Bioorganic & Medicinal Chemistry Letters. 26(3). 742–746. 20 indexed citations
17.
Menezes, Daniel L., Yan Tang, Jiajia Feng, et al.. (2014). A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-Function. Molecular Cancer Research. 13(1). 120–129. 78 indexed citations
18.
Menezes, Daniel L., Pietro Taverna, Michael Rugaard Jensen, et al.. (2012). The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo. Molecular Cancer Therapeutics. 11(3). 730–739. 57 indexed citations
19.
Xin, Xiaohua, Yan Tang, Yoko Oei, et al.. (2005). CHIR-258 Efficacy in a Newly Developed Preclinical Bone Marrow Model of t(4;14) Multiple Myeloma.. Blood. 106(11). 3449–3449. 1 indexed citations
20.
Menezes, Daniel L. & Lawrence D. Mayer. (2002). Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Cancer Chemotherapy and Pharmacology. 49(1). 57–68. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Koshi Akahane Breakdown of academic impact, for papers by Sharon Friedlander Breakdown of academic impact, for papers by Nguyen Tan Breakdown of academic impact, for papers by Dina Ali Breakdown of academic impact, for papers by Paul A. Algate Breakdown of academic impact, for papers by Davide Torti Breakdown of academic impact, for papers by S. Pezzulli Breakdown of academic impact, for papers by X. Zhang Breakdown of academic impact, for papers by Dan Lu Breakdown of academic impact, for papers by Glenn Michelson
Rankless by CCL
2026